Addisons Disease Drugs Market 2028 By Drug Class, Route of Administration, End Use, and Geography | The Insight Partners

report image

Addisons Disease Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Glucocorticoid, Mineralocorticoid, and Others); Route of Administration (Oral, Parenteral, and Others); End Use (Hospitals, Homecare, Specialty Clinics, and Others), and Geography

Report Code: TIPRE00023421 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Addisons Disease drugs, also termed hypocortisolism or primary adrenal insufficiency, are potentially life-threatening conditions in which the body does not produce enough cortisol or aldosterone. The characteristics sign and symptoms of Addisons Disease fatigue, nausea, darkening of the skin, and dizziness. Addisons Disease demands lifelong treatment with steroid replacement therapy. Glucocorticoid and mineralocorticoid replacement therapy is presently most widely used for the treatment of Addisons Disease. Additional, hydrocortisone is one of the most preferred drugs belonging to the glucocorticoid class due to its short half-life, which enables it to be quickly absorbed into the bloodstream.


The "Global Addisons Disease drugs Market Analysis to 2028" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Addisons Disease drugs market with detailed market segmentation by drug class, route of administration, end use, and geography. The report provides key statistics on the market status of the leading Addisons Disease drugs market players and offers key trends and opportunities in the market.


  •  Based on drug class, the global Addisons Disease drugs market is segmented into glucocorticoid, mineralocorticoid and others.
  •  On the basis of route of administration, the market is segmented into oral, parenteral and others.
  •  On the basis of end use, the market is segmented into hospitals, homecare, specialty clinics and others.


  •  Growing cases of Addisons Disease.
  •  Rise in the research and development activities by pharmaceutical companies.
  •  Rise in patient awareness.
  •  Advancements in treatment options.


  •  The product recalls and misuse of drug are the major restraining factor for this market.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Addisons Disease drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Addisons Disease drugs market in these regions.


COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

Get more information on this report :


The report covers key developments in the Addisons Disease drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Addisons Disease drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Addisons Disease drugs in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Addisons Disease drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Bristol-Myers Squibb Company
  •  Merck and Co., Inc
  •  Novartis AG
  •  Pfizer Inc
  •  Takeda Pharmaceutical Company Limited
  •  Bio-Techne
  •  GlaxoSmithKline plc
  •  Lupin
  •  Abbott
  •  Amgen Inc

The Insight Partner's dediAddisons Disease drugsed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Get more information on this report :

The List of Companies

1. Bristol-Myers Squibb Company
2. Merck and Co., Inc
3. Novartis AG
4. Pfizer Inc
5. Takeda Pharmaceutical Company Limited
6. Bio-Techne
7. GlaxoSmithKline plc
8. Lupin
9. Abbott
10. Amgen Inc
11. Bayer AG
12. Biogen
13. Eli Lilly and Company
14. ViroPharma
15. Tocris Bioscience
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount